Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of “Hold” from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received a consensus rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $37.83.

OMCL has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Benchmark reiterated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. Bank of America increased their price objective on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Wells Fargo & Company boosted their target price on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the period. EntryPoint Capital LLC lifted its position in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after purchasing an additional 1,345 shares during the period. CWM LLC boosted its stake in shares of Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. grew its position in shares of Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Omnicell during the second quarter worth approximately $104,000. 97.70% of the stock is owned by institutional investors.

Omnicell Price Performance

Shares of OMCL stock opened at $43.42 on Friday. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.58. The company has a market capitalization of $2.00 billion, a P/E ratio of -94.39, a P/E/G ratio of 47.22 and a beta of 0.83. The stock has a 50 day moving average of $38.85 and a two-hundred day moving average of $32.12. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. As a group, equities analysts expect that Omnicell will post 0.64 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.